JP2017507150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507150A5 JP2017507150A5 JP2016555457A JP2016555457A JP2017507150A5 JP 2017507150 A5 JP2017507150 A5 JP 2017507150A5 JP 2016555457 A JP2016555457 A JP 2016555457A JP 2016555457 A JP2016555457 A JP 2016555457A JP 2017507150 A5 JP2017507150 A5 JP 2017507150A5
- Authority
- JP
- Japan
- Prior art keywords
- sdc
- trap
- daltons
- moiety
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 claims 14
- 239000012636 effector Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 2
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 2
- 229950007866 tanespimycin Drugs 0.000 claims 2
- 239000004066 vascular targeting agent Substances 0.000 claims 2
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 claims 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 claims 1
- 206010020649 Hyperkeratosis Diseases 0.000 claims 1
- 208000001126 Keratosis Diseases 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 229930195248 Macbecin Natural products 0.000 claims 1
- PLTGBUPHJAKFMA-UHFFFAOYSA-N Macbecin I Natural products N1C(=O)C(C)=CC=CC(C)C(OC(N)=O)C(C)=CC(C)C(OC)C(OC)CC(C)C(OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-UHFFFAOYSA-N 0.000 claims 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims 1
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 claims 1
- 229940079156 Proteasome inhibitor Drugs 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims 1
- PLTGBUPHJAKFMA-BMJWZTMLSA-N [(2r,3s,5s,6r,7s,8e,10r,11s,12z,14e)-2,5,6-trimethoxy-3,7,9,11,15-pentamethyl-16,20,22-trioxo-17-azabicyclo[16.3.1]docosa-1(21),8,12,14,18-pentaen-10-yl] carbamate Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](C)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](OC)[C@@H](OC)C[C@H](C)[C@@H](OC)C2=CC(=O)C=C1C2=O PLTGBUPHJAKFMA-BMJWZTMLSA-N 0.000 claims 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 claims 1
- 229960000853 abiraterone Drugs 0.000 claims 1
- 230000009056 active transport Effects 0.000 claims 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 claims 1
- 229950010817 alvocidib Drugs 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 1
- 229960003005 axitinib Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 1
- 229960002438 carfilzomib Drugs 0.000 claims 1
- 108010021331 carfilzomib Proteins 0.000 claims 1
- KQJSQWZMSAGSHN-JJWQIEBTSA-N celastrol Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)[C@](C)(C(O)=O)CC[C@]1(C)CC[C@]2(C)C4=CC=C1C3=CC(=O)C(O)=C1C KQJSQWZMSAGSHN-JJWQIEBTSA-N 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 230000001973 epigenetic effect Effects 0.000 claims 1
- 150000002148 esters Chemical group 0.000 claims 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 229960002258 fulvestrant Drugs 0.000 claims 1
- 229950004161 ganetespib Drugs 0.000 claims 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical group N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- QRMNENFZDDYDEF-GOSISDBHSA-N methyl (8s)-8-(bromomethyl)-2-methyl-4-(4-methylpiperazine-1-carbonyl)oxy-6-(5,6,7-trimethoxy-1h-indole-2-carbonyl)-7,8-dihydro-3h-pyrrolo[3,2-e]indole-1-carboxylate Chemical compound C1([C@H](CBr)CN(C1=C1)C(=O)C=2NC3=C(OC)C(OC)=C(OC)C=C3C=2)=C2C(C(=O)OC)=C(C)NC2=C1OC(=O)N1CCN(C)CC1 QRMNENFZDDYDEF-GOSISDBHSA-N 0.000 claims 1
- VYGYNVZNSSTDLJ-HKCOAVLJSA-N monorden Natural products CC1CC2OC2C=C/C=C/C(=O)CC3C(C(=CC(=C3Cl)O)O)C(=O)O1 VYGYNVZNSSTDLJ-HKCOAVLJSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 claims 1
- 229960005184 panobinostat Drugs 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- AECPBJMOGBFQDN-YMYQVXQQSA-N radicicol Chemical compound C1CCCC(=O)C[C@H]2[C@H](Cl)C(=O)CC(=O)[C@H]2C(=O)O[C@H](C)C[C@H]2O[C@@H]21 AECPBJMOGBFQDN-YMYQVXQQSA-N 0.000 claims 1
- 229930192524 radicicol Natural products 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 1
- 229960003862 vemurafenib Drugs 0.000 claims 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims 1
- 229960000237 vorinostat Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947108P | 2014-03-03 | 2014-03-03 | |
| US61/947,108 | 2014-03-03 | ||
| PCT/US2015/018442 WO2015134464A2 (en) | 2014-03-03 | 2015-03-03 | Targeted therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151197A Division JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2017507150A JP2017507150A (ja) | 2017-03-16 |
| JP2017507150A5 true JP2017507150A5 (enExample) | 2018-04-12 |
| JP6576942B2 JP6576942B2 (ja) | 2019-09-18 |
| JP6576942B6 JP6576942B6 (ja) | 2019-11-27 |
Family
ID=54055980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016555457A Expired - Fee Related JP6576942B6 (ja) | 2014-03-03 | 2015-03-03 | 標的治療薬 |
| JP2019151197A Pending JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151197A Pending JP2019196406A (ja) | 2014-03-03 | 2019-08-21 | 標的治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10232049B2 (enExample) |
| EP (1) | EP3129064B1 (enExample) |
| JP (2) | JP6576942B6 (enExample) |
| KR (1) | KR20160126078A (enExample) |
| CN (1) | CN106456795A (enExample) |
| AU (1) | AU2015224576A1 (enExample) |
| CA (1) | CA2941618A1 (enExample) |
| IL (1) | IL247624A0 (enExample) |
| MA (1) | MA39481A (enExample) |
| WO (1) | WO2015134464A2 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3131586A4 (en) * | 2014-03-18 | 2017-10-25 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| LT3660004T (lt) * | 2016-10-11 | 2023-06-12 | Arvinas Operations, Inc. | Junginiai ir metodai, skirti tikslinei androgeno receptoriaus degradacijai |
| JP2020524156A (ja) * | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的治療薬を含む併用療法 |
| JP2020524154A (ja) * | 2017-06-20 | 2020-08-13 | マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 標的治療薬 |
| US20200230247A1 (en) * | 2017-06-20 | 2020-07-23 | Tarveda Therapeutics, Inc. | Combination therapies comprising targeted therapeutics |
| CN109512821B (zh) * | 2017-09-18 | 2021-06-08 | 无锡富泽药业有限公司 | 一种克唑替尼与17-aag复合聚合物纳米胶束注射剂、其制备方法及其应用 |
| AU2018386218A1 (en) * | 2017-12-14 | 2020-07-02 | Tva (Abc), Llc | HSP90-targeting conjugates and formulations thereof |
| SG11202011135WA (en) | 2018-05-14 | 2020-12-30 | Nuvation Bio Inc | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP3801506A4 (en) * | 2018-06-01 | 2022-08-10 | Tva (Abc), Llc | POLYTHERAPY |
| CN109575044A (zh) * | 2018-12-21 | 2019-04-05 | 西安交通大学 | 2-（喜树碱-10-氧基）乙酰胺类化合物和应用 |
| JP7644713B2 (ja) | 2019-03-06 | 2025-03-12 | プロペラ セラピューティクス インコーポレイテッド | アビラテロンプロドラッグ |
| WO2020210451A1 (en) * | 2019-04-10 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (fgfr2) |
| US11826430B2 (en) | 2019-05-14 | 2023-11-28 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN110003181B (zh) * | 2019-05-22 | 2020-08-28 | 北京凯恩梅格医药科技有限公司 | 一种基于克唑替尼结构的c-Met/HDAC双靶点抑制剂及其合成方法与应用 |
| EP4126833B1 (en) * | 2020-03-23 | 2026-05-20 | Helmholtz Zentrum Infektionsforschung Gmbh | N-PHENYL-3-MERCAPTOPROPANAMIDES DERIVATIVES AS METALLO-BETA-LACTAMASES INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS |
| CN111499623B (zh) * | 2020-04-01 | 2022-07-08 | 南京缘聚医药科技有限公司 | 一类非核苷抗肿瘤药物的噻唑酮脲衍生物及其药物用途 |
| EP4146642A1 (en) | 2020-05-09 | 2023-03-15 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CA3207282A1 (en) | 2021-02-15 | 2022-08-18 | Matthew J. Sharp | Abiraterone prodrugs |
| KR20230160299A (ko) | 2021-03-23 | 2023-11-23 | 누베이션 바이오 인크. | 항암 핵 호르몬 수용체 표적화 화합물 |
| US12006314B2 (en) | 2021-05-03 | 2024-06-11 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN114933584B (zh) * | 2021-08-09 | 2022-12-27 | 上海贵之言医药科技有限公司 | 一种二氢-2h-异吲哚酯类化合物 |
| CN116354933B (zh) * | 2021-12-27 | 2025-06-20 | 青岛普泰科生物医药科技有限公司 | 作为雄激素受体调节剂的杂环化合物及其应用 |
| CN115650975B (zh) * | 2022-08-23 | 2024-07-02 | 四川大学华西医院 | 一种靶向降解人表皮生长因子受体2的蛋白降解靶向嵌合体化合物及其应用 |
| WO2024197429A1 (zh) * | 2023-03-24 | 2024-10-03 | 青岛普泰科生物医药科技有限公司 | 作为雄激素受体调节剂的杂环化合物及其应用 |
| CN117720514A (zh) * | 2023-03-31 | 2024-03-19 | 福建医科大学 | 一种基于分子胶原理降解Hsp90的化合物、其制备方法及其在治疗肿瘤中的应用 |
| CN121487739A (zh) * | 2023-03-31 | 2026-02-06 | 珃诺生物医药科技(杭州)有限公司 | 用于靶向蛋白降解的方法和组合物 |
| WO2025122895A1 (en) | 2023-12-08 | 2025-06-12 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025199665A1 (en) * | 2024-03-23 | 2025-10-02 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| ATE473759T1 (de) | 1998-05-22 | 2010-07-15 | Univ Leland Stanford Junior | Bifunktionelle moleküle sowie darauf basierende therapien. |
| US8617514B2 (en) | 1999-02-22 | 2013-12-31 | Georgetown University | Tumor-targeted nanodelivery systems to improve early MRI detection of cancer |
| AU769235B2 (en) | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| EP1337275A4 (en) | 2000-11-02 | 2007-05-09 | Sloan Kettering Inst Cancer | METHOD FOR ENHANCING THE EFFICACY OF CYTOTOXIC AGENTS USING HSP 90 INHIBITORS |
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| JP2005520795A (ja) | 2001-12-12 | 2005-07-14 | コンフォーマ・セラピューティクス・コーポレイション | Ｈｓｐ９０阻害活性を有するプリン類似体 |
| GB0211578D0 (en) | 2002-05-21 | 2002-06-26 | Univ Belfast | Medicaments |
| US6759416B2 (en) | 2002-08-06 | 2004-07-06 | Panorama Research, Inc. | Anticancer conjugates of camptothecin and unsaturated fatty acids |
| US7769423B2 (en) | 2002-09-11 | 2010-08-03 | Duke University | MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting |
| EP1581261A4 (en) | 2002-12-12 | 2009-10-21 | Conforma Therapeutics Corp | Cytotoxins and agents for diagnostic imaging with HSP90 ligands |
| WO2005095347A1 (en) | 2004-03-26 | 2005-10-13 | Van Andel Research Institute | Geldanamycin and derivatives inhibit cancer invasion and identify novel targets |
| EP2298748B1 (en) | 2004-11-18 | 2016-07-20 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| WO2006084030A2 (en) | 2005-02-01 | 2006-08-10 | Sloan-Kettering Institute For Cancer Research | Small-molecule hsp90 inhibitors |
| WO2007053792A2 (en) | 2005-11-05 | 2007-05-10 | Amplyx Pharmaceuticals, Inc. | Improving the pharmacokinetics of protease inhibitors and other drugs |
| US8293726B2 (en) | 2005-12-02 | 2012-10-23 | Vianova Labs, Inc. | Treatment of cancer and other diseases |
| GB0526615D0 (en) | 2005-12-30 | 2006-02-08 | Novartis Ag | Organic compounds |
| TWI490212B (zh) | 2006-05-25 | 2015-07-01 | Synta Pharmaceuticals Corp | 調節ｈｓｐ９０活性之三唑化合物 |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP5721949B2 (ja) | 2006-10-12 | 2015-05-20 | アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 複合薬剤 |
| WO2008057246A2 (en) | 2006-10-26 | 2008-05-15 | Synta Pharmaceuticals Corp. | Method for treating inflammatory disorders |
| CA2680161A1 (en) | 2007-03-05 | 2008-09-12 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical composition |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| EP2180880A2 (en) | 2007-07-09 | 2010-05-05 | Glen S. Kwon | Micelle encapsulation of therapeutic agents |
| CN101854955B (zh) | 2007-09-10 | 2012-07-18 | 马萨诸塞大学 | 靶向线粒体的抗肿瘤剂 |
| US20110270151A1 (en) | 2008-09-08 | 2011-11-03 | The Methodist Hospital Research Institute | Image-guided energy deposition for targeted drug delivery |
| WO2011116181A1 (en) | 2010-03-17 | 2011-09-22 | Caris Life Sciences, Inc. | Theranostic and diagnostic methods using sparc and hsp90 |
| US8546425B2 (en) | 2008-09-17 | 2013-10-01 | Purdue Research Foundation | Folate receptor binding conjugates of antifolates |
| US20110217241A1 (en) | 2008-11-14 | 2011-09-08 | University Of Maryland, Baltimore | Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging |
| PE20120630A1 (es) * | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| US20110268722A1 (en) | 2010-04-22 | 2011-11-03 | Siegelin Markus D | Combination therapies with mitochondrial-targeted anti-tumor agents |
| KR20140021520A (ko) | 2010-10-22 | 2014-02-20 | 위니베르시떼 드 스트라스부르 | Hsp90 관련 질환의 치료에 유용한 포코옥심 컨쥬게이트 |
| EP2663305A1 (en) * | 2011-01-11 | 2013-11-20 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors |
| GB201106814D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| EP2766723A4 (en) * | 2011-10-12 | 2015-06-10 | Univ North Carolina | MULTIPLEXED KINASE HEMMER BEADS AND THEIR USE |
| CA2855368A1 (en) * | 2011-11-11 | 2013-05-16 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CA2865021C (en) * | 2012-02-23 | 2020-06-30 | Bayer Intellectual Property Gmbh | Substituted benzothienyl-pyrrolotriazines and uses thereof |
| US20140079636A1 (en) * | 2012-04-16 | 2014-03-20 | Dinesh U. Chimmanamada | Targeted therapeutics |
| EP3925627A1 (en) | 2012-05-15 | 2021-12-22 | Concortis Biosystems, Corp | Drug-conjugates and uses thereof |
| AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
| EP3035938B1 (en) | 2013-09-10 | 2020-08-19 | Madrigal Pharmaceuticals, Inc. | Targeted therapeutics |
| KR102087850B1 (ko) | 2013-10-11 | 2020-03-12 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-고분자-약물 접합체 |
| EP3057610B1 (en) | 2013-10-15 | 2021-09-22 | Sorrento Therapeutics, Inc. | Drug-conjugates with a targeting molecule and two different drugs |
| WO2015066053A2 (en) | 2013-10-28 | 2015-05-07 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
| EP4062917B1 (en) | 2013-12-20 | 2025-12-03 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of pi3k/akt pathway and erk inhibitors |
| WO2015116774A1 (en) | 2014-01-29 | 2015-08-06 | Synta Pharmaceuticals Corp. | Targeted therapeutics |
-
2015
- 2015-03-03 CN CN201580022696.0A patent/CN106456795A/zh active Pending
- 2015-03-03 EP EP15758717.1A patent/EP3129064B1/en active Active
- 2015-03-03 KR KR1020167027259A patent/KR20160126078A/ko not_active Withdrawn
- 2015-03-03 WO PCT/US2015/018442 patent/WO2015134464A2/en not_active Ceased
- 2015-03-03 AU AU2015224576A patent/AU2015224576A1/en not_active Abandoned
- 2015-03-03 MA MA039481A patent/MA39481A/fr unknown
- 2015-03-03 JP JP2016555457A patent/JP6576942B6/ja not_active Expired - Fee Related
- 2015-03-03 CA CA2941618A patent/CA2941618A1/en not_active Abandoned
-
2016
- 2016-08-30 US US15/251,255 patent/US10232049B2/en active Active
- 2016-09-04 IL IL247624A patent/IL247624A0/en unknown
-
2018
- 2018-10-25 US US16/170,733 patent/US10675360B2/en not_active Expired - Fee Related
-
2019
- 2019-08-21 JP JP2019151197A patent/JP2019196406A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512953A5 (enExample) | ||
| JP2017505777A5 (enExample) | ||
| IL293316A (en) | Targeted therapeutics | |
| SA521421855B1 (ar) | مترافقات عقار-جسم مضاد | |
| NL300929I2 (nl) | Telotristat, desgewenst in de vorm van een farmaceutisch aanvaardbaar ester of zout, in het bijzonder telotristat ethyl, meer in het bijzonder het hippuraat zout van telotristat ethyl | |
| WO2018098269A2 (en) | Peptide-containing linkers for antibody-drug conjugates | |
| EP2708256A3 (en) | Device and method for delivery of a medicament | |
| WO2017059224A3 (en) | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers | |
| ATE472338T1 (de) | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs | |
| WO2009027644A3 (en) | Compositions for the treatment of neoplastic diseases | |
| EP4378482A3 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| WO2008083174A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| CA2944480C (en) | Local drug delivery devices and methods for treating cancer | |
| AU2012395673A8 (en) | Rapamycin analogs and methods for making same | |
| NZ597051A (en) | Smac mimetic | |
| MX2009012155A (es) | Combinación farmacéutica sinérgica para el tratamiento de cáncer. | |
| JP2012512158A5 (enExample) | ||
| WO2007084661A3 (en) | Therapy-enhancing glucan | |
| MX2014014969A (es) | Combinacion de un inhibidor de la 17-alfa-hidroxilasa (c17,20-liasa) y un inhibidor especifico de la pi-3k para tratar una enfermedad tumoral. | |
| EP1829882A3 (en) | Epimers and isomers of tetrazole containing rapamycin analogs, methods of making and using the same | |
| JP2010523696A5 (enExample) | ||
| CU23798B6 (es) | Combinación farmacéutica que emplea anticuerpos contra el receptor del factor de crecimiento epidérmico y agentes inmunosupresores | |
| JP2019509986A (ja) | トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 | |
| JP2018527360A5 (enExample) | ||
| WO2008089185A3 (en) | Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof |